Claire Mazumdar, Bicara Therapeutics CEO
Early data show Bicara’s bispecific helps shrink head and neck cancers when combined with Keytruda: #ASCO23
Bicara’s bispecific antibody treatment on top of Keytruda led to tumor shrinkage in about half of patients with head and neck cancer that has relapsed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
